Sun Pharma’s Secret Sauce: Solve the Specific, Win the Market
India’s largest drugmaker underscores that precision—designing drugs to reduce side effects and improve delivery for very specific patient needs—beats scattershot expansion, Executive Chairman Dilip Shanghvi said, noting annual R&D of about $450 million, strong specialty anchors like Ilumya (FY25 sales ~$681m), and momentum from Leqselvi in alopecia areata; two-thirds of revenue now comes from international markets, and even the long, messy Ranbaxy integration “doesn’t mean the strategy was wrong—only execution must improve.”
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-07-09
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Betting on Next-Generation Metabolic Therapies: Pfizer’s Big Wager on Metsera and Its Strategic Reshaping in China
-
Novo Nordisk Reports Theft of Six Drug Batches in India Authorities Warn of Severe Patient Safety Risks
-
Parliamentary Panel Urges Expanded Price Controls as Dozens of Cancer Drugs Remain Unregulated
-
Glenmark Recalls Over 110000 Bottles of BP and COPD Drugs in US Due to Safety Concerns
-
Small Pharma Firms Under Threat as Regulator Tightens Quality Norms
-
Merck Nears Acquisition of Cidara to Strengthen Flu Prevention Arsenal
-
Biocon Weighs Merger of Biocon Biologics to Unlock Value
-
Sun Pharma’s Utreglutide Shows Promising Weight Loss and Liver Fat Reduction
-
The GLP-1 Sweet Shot in India’s Diabetic Gut
-
Novo Nordisk Submits Higher Dose of Wegovy One in Three Achieves Over 25 Percent Weight Loss
Recommend Reading
-
Glenmark’s $1 Billion Cancer Bet: Oncology Revolution Set to Ignite in FY28
-
FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers
-
BASF’s Price Increase Shows Pharma Excipients Are Still Exposed to Chemical Cost Pressure
-
Lilly’s Indiana Investment Puts API Capacity at the Center of Obesity Drug Competition
-
After Semaglutide Patent Expiry in India, the Price System Has Been Restructured as More Than 40 Drugmakers Enter the Competition
-
Supply Decreases and Demand Increases, DOP Prices Surge Significantly in January
-
This week, the domestic anhydrous hydrogen fluoride market maintained a high-level consolidation operation (3.16-3.19)
-
BASF and Clariant Exit Quietly! Behind Henkel’s High-Priced Acquisition, Why Did Former Allies Choose to “Let Go”?
-
Qatar LNG Hit by Attack: 17% Export Capacity Lost, $20 Billion Wiped Out
-
Premium Global Chemical Sourcing Requests (31 Jan - 4 Feb, 2026)